Acadiana Oncology

CLIA Laboratory Citation Details

3
Total Citations
60
Total Deficiencyies
22
Unique D-Tags
CMS Certification Number 19D0993289
Address 602 North Lewis Street, Suite 600, New Iberia, LA, 70563
City New Iberia
State LA
Zip Code70563
Phone337 560-5510
Lab DirectorMARK CHARBONNET

Citation History (3 surveys)

Survey - August 29, 2024

Survey Type: Standard

Survey Event ID: W87C11

Deficiency Tags: D2009 D5221 D2009 D5221 D5291 D6019 D6021 D6019 D0000 D5291 D5413 D6014 D6016 D5413 D6014 D6016 D6021

Summary:

Summary Statement of Deficiencies D0000 A Recertification survey was performed on August 29, 2024 at Acadiana Oncology, CLIA ID # 19D0993289. The laboratory was found in compliance with 42 CFR 493 Requirements for Laboratories; however, standard level deficiencies were cited. D2009 TESTING OF PROFICIENCY TESTING SAMPLES CFR(s): 493.801(b)(1) The individual testing or examining the samples and the laboratory director must attest to the routine integration of the samples into the patient workload using the laboratory's routine methods. This STANDARD is not met as evidenced by: Based on review of proficiency testing records and as interview with personnel, the laboratory failed to ensure the Testing Personnel and Laboratory Director signed the attestation statement for three (3) of six (6) proficiency testing (PT) events reviewed. Findings: 1. Review of the laboratory's American Proficiency Institute (API) proficiency testing records revealed the Laboratory Director and/or Testing Personnel did not sign the following attestation statements: a) 2023 Hematology/Coagulation - 2nd event: Not signed by the Laboratory Director and Testing Personnel b) 2023 Hematology/Coagulation - 3rd event: Not signed by the Laboratory Director c) 2024 Hematology/Coagulation - 2nd event: Not signed by the Laboratory Director 2. In interview on August 29, 2024 at 2 p.m., Testing Personnel 1 confirmed the attestation sheets were not signed as identified above. D5221 EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(d) All proficiency testing evaluation and verification activities must be documented. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 4 -- This STANDARD is not met as evidenced by: Based on review of the laboratory's policies, proficiency testing records, and interview with personnel, the laboratory failed to perform an assessment for unacceptable proficiency testing (PT) results for one (1) of six (6) events reviewed. Findings: 1. Review of the laboratory's "Quality Assurance Program" policy under the "Proficiency Testing" section revealed "PT results are reviewed and retained for a period of at least two years. PT failures are investigated and remedial action is taken." 2. Review of the laboratory's "API Quarterly Event Testing Checklist" revealed "When results are less than 100% -

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - September 28, 2022

Survey Type: Standard

Survey Event ID: G38011

Deficiency Tags: D0000 D5211 D5401 D5415 D6014 D0000 D5211 D5401 D5415 D6014 D6018 D6031 D6018 D6031

Summary:

Summary Statement of Deficiencies D0000 A Recertification survey was performed on September 28, 2022 at Acadiana Oncology, CLIA ID # 19D0993289. The laboratory was found in compliance with 42 CFR 493 Requirements for Laboratories; however, standard level deficiencies were cited. D5211 EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(a) The laboratory must review and evaluate the results obtained on proficiency testing performed as specified in subpart H of this part. This STANDARD is not met as evidenced by: Based on review of the laboratory's policies, proficiency test records, and interview with personnel, the laboratory failed to maintain and ensure the Laboratory Director reviewed the proficiency testing (PT) performance evaluation results for one (1) of five (5) events reviewed. Findings: 1. Review of the laboratory's "Quality Assurance Program" policy under the "Proficiency Testing" section revealed "PT results are reviewed and retained for a period of at least two years. PT failures are investigated and remedial action is taken." 2. Review of the American Proficiency Institute (API) proficiency testing records for 2021 and 2022 revealed the laboratory did not maintain the evaluation form and documentation of the Laboratory Director's review/signature for the 2022 Hematology/Coagulation 2nd Event. 3. In interview on September 28, 2022 at 2:42 pm, Testing Personnel 1 confirmed the laboratory did not have the evaluation form for the 2022 Hematology/Coagulation 2nd PT Event . D5401 PROCEDURE MANUAL CFR(s): 493.1251(a) A written procedures manual for all tests, assays, and examinations performed by the laboratory must be available to, and followed by, laboratory personnel. Textbooks Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- may supplement but not replace the laboratory's written procedures for testing or examining specimens. This STANDARD is not met as evidenced by: Based on review of the laboratory's policy and procedure manual and interview with personnel, the laboratory failed to establish complete proficiency testing (PT) policies. Findings: 1. Review of the laboratory's "Quality Assurance Program" policy under the "Proficiency Testing" section revealed "PT results are reviewed and retained for a period of at least two years. PT failures are investigated and remedial action is taken." 2. Further review of the laboratory's "Proficiency Testing" policy revealed the laboratory did not include detailed written instructions related to the remedial actions to take for PT failures. 3. In interview on September 28, 2022 at 2:42 pm, Testing Personnel 1 confirmed the laboratory's policy related to proficiency testing did not include detailed written instructions for actions and investigative steps to take for PT failures. D5415 TEST SYSTEMS, EQUIPMENT, INSTRUMENTS, REAGENT CFR(s): 493.1252(c) Reagents, solutions, culture media, control materials, calibration materials, and other supplies, as appropriate, must be labeled to indicate the following: (1) Identity and when significant, titer, strength or concentration. (2) Storage requirements. (3) Preparation and expiration dates. (4) Other pertinent information required for proper use. This STANDARD is not met as evidenced by: Based on observation by surveyor, review of manufacturer instructions, and interview with personnel, the laboratory failed to label hematology controls with updated expiration dates after opening. Findings: 1. Observation by surveyor during the laboratory tour on September 28, 2022 at 1:04 pm revealed the laboratory stored open Sysmex EightCheck -3 WP X-tra hematology controls ( Lot Number: 219307) in a refrigerator without labeling with the "open" and updated "expiration" dates. 2. Review of the Sysmex EightCheck -3WP Xtra manufacturer's instructions under the "Storage and shelf life after first opening" section revealed "Opened and recapped vials and vials whose caps have ben pierced will retain stability for 14 days if stored at 2-8 C after being re-capped." 3. In interview on September 28, 2022 at 1:04 pm, Testing Personnel 1 stated the laboratory maintains a log that includes the expiration date for hematology controls. Testing Personnel 1 confirmed the laboratory does not label the in-use hematology control vials with "open" and "expiration" dates. D6014 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(3)(iii) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(3) Ensure that-- (e)(3)(iii) Laboratory personnel are performing the test methods as required for accurate and reliable results. -- 2 of 3 -- This STANDARD is not met as evidenced by: Based on observation by surveyor, record review, and interview with personnel, the Laboratory Director failed to ensure the laboratory personnel performed test methods as required. Refer to D5415. D6018 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(iii) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(4)(iii) Ensure that all proficiency testing reports received are reviewed by the appropriate staff to evaluate the laboratory's performance and to identify any problems that require

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - January 27, 2021

Survey Type: Standard

Survey Event ID: 4TPD11

Deficiency Tags: D5221 D5401 D5403 D5421 D5439 D5421 D5439 D5791 D5805 D5891 D6013 D6014 D6019 D6021 D0000 D5221 D5401 D5403 D5791 D5805 D5891 D6013 D6014 D6019 D6021 D6026 D6031 D6026 D6031

Summary:

Summary Statement of Deficiencies D0000 A Recertification survey was performed on January 27, 2021 at Acadiana Oncology, CLIA ID # 19D0993289. The laboratory was found in compliance with 42 CFR 493 Requirements for Laboratories; however, standard level deficiencies were cited. D5221 EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(d) All proficiency testing evaluation and verification activities must be documented. This STANDARD is not met as evidenced by: Based on review of the laboratory's proficiency testing records and interview with personnel, the laboratory failed to perform an assessment for Hematology proficiency test (PT) results that scored less than 100 hundred (100%). Findings: 1. Review of the laboratory's American Proficiency Institute (API) PT results revealed the laboratory received the following "unacceptable" results: 2019 3rd Event: Sample HSY-12 for Lymphocytes, API grade: "unacceptable"-80% 2020 3rd Event: Sample HSY-12 for MCH, API grade: "unacceptable"-80 % 2. Review of the laboratory's PT records revealed the laboratory did not perform assessments for the "unacceptable" API PT results. 3. In interview on January 27, 2021 at 2:28 pm, Testing Personnel 1 stated the laboratory did not perform assessments for the identified PT results. D5401 PROCEDURE MANUAL CFR(s): 493.1251(a) A written procedures manual for all tests, assays, and examinations performed by the laboratory must be available to, and followed by, laboratory personnel. Textbooks may supplement but not replace the laboratory's written procedures for testing or examining specimens. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 7 -- This STANDARD is not met as evidenced by: Based on review of the laboratory's policy and procedure manual and interview with personnel, the laboratory failed to establish a complete policy and procedure manual. Findings: 1. Review of the laboratory's policy and procedure manual revealed the laboratory did not have written policies and procedures that included: a) Performance specification: detailed procedures for performing accuracy and precision (day-to-day, run-to-run, and within-run variation, as well as operator variance), reportable and reference range studies, acceptability criteria for studies, and actions to take when data from the studies fail to meet acceptability criteria 2. In interview on January 27, 2021 at 2:02 pm, Testing Personnel 1 confirmed the laboratory did not have a policy for performance specification studies for new tests/analyzers. D5403 PROCEDURE MANUAL CFR(s): 493.1251(b) The procedure manual must include the following when applicable to the test procedure: (1) Requirements for patient preparation; specimen collection, labeling, storage, preservation, transportation, processing, and referral; and criteria for specimen acceptability and rejection as described in 493.1242. (2) Microscopic examination, including the detection of inadequately prepared slides. (3) Step-by-step performance of the procedure, including test calculations and interpretation of results. (4) Preparation of slides, solutions, calibrators, controls, reagents, stains, and other materials used in testing. (5) Calibration and calibration verification procedures. (6) The reportable range for test results for the test system as established or verified in 493.1253. (7) Control procedures. (8)

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access